Increased PLA2 activity in individuals at ultra-high risk for psychosis

Eur Arch Psychiatry Clin Neurosci. 2021 Dec;271(8):1593-1599. doi: 10.1007/s00406-021-01246-y. Epub 2021 Mar 6.

Abstract

Phospholipase A2 is the main enzyme in the metabolism of membrane phospholipids. It comprises a family of enzymes divided into iPLA2, cPLA2 and sPLA2. Studies have reported increased PLA2 activity in psychotic patients, which suggests an accelerated breakdown of membrane phospholipids. In the present study we investigated whether increased PLA2 activity is also present in individuals at ultra-high risk (UHR) for psychosis. One-hundred fifty adults were included in this study (85 UHR and 65 controls). UHR was assessed using the "structured interview for prodromal syndromes". PLA2 activity was determined in platelets by a radio-enzymatic assay. We found in UHR individuals increased activities of iPLA2 (p < 0.001) and cPLA2 (p = 0.012) as compared to controls. No correlations were found between socio-demographic and clinical parameters and PLA2 activity. Our findings suggest that increased PLA2 activities may be useful as a biological risk-marker for psychotic disorders.

Keywords: Biomarkers; Phospholipase A2; Platelets; Psychosis; Ultra-high risk.

MeSH terms

  • Adult
  • Biomarkers / metabolism
  • Humans
  • Phospholipases A2* / metabolism
  • Psychotic Disorders* / epidemiology
  • Psychotic Disorders* / metabolism
  • Risk Assessment

Substances

  • Biomarkers
  • Phospholipases A2